News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Erick Saldanha: The role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade in solid tumours
Erick Saldanha and Luís Felipe Leite
Apr 6, 2025, 13:37

Erick Saldanha: The role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade in solid tumours

Erick Saldanha, Medical Oncologist and Postdoctoral Clinical Fellow at Princess Margaret Cancer Centre, shared a post on X:

“Thrilled to share our paper, just out in the Annals of Oncology, ESMO.

We assessed the role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade response for patients with solid tumours. Proud to be part of this effort alongside a brilliant group of colleagues and my dear friend Valenza Carmine.

Check out the article ”

Luís Felipe Leite, Medical Student at Universidade Federal Fluminense, shared Erick Saldanha‘s post on X, adding:

“Absence of ctDNA clearance may identify patients unlikely to achieve pCR after neoadjuvant ICIs.

However, limited specificity means current evidence does not support its use to guide treatment de-escalation. Impressive analysis by Dr. Saldanha in the Annals of Oncology.”

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Authors: Valenza Carmine, Erick Saldanha et al.

Erick Saldanha

 

Learn more about immunotherapy on OncoDaily.

A.H. Partridge Annals of Oncology C. Cremolini C. Valenza cancer D. Gritsch D. Trapani E.F. Saldanha ESMO F. Conforti G Curigliano H. Ortiz H.A. Parsons J. Mateo OncoDaily Oncology P De Placido S. Peters V Subbiah Valenza Carmine Y. Gong
Special Coverage
Insight
Apr 6, 2025, 13:37
Erick Saldanha: The role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade in solid tumours
Opinion
Apr 6, 2025, 13:15
Sumanta Pal honors Evita Sadimin’s impact on oncology teams at the City of Hope Doctors Day Ceremony
Opinion
Apr 6, 2025, 12:55
Fumiko Ladd Chino: Toxicity in phase III oncology clinical trials is often incompletely reported
Insight
Apr 6, 2025, 12:51
Carolina Reduzzi and Lorenzo Gerratana on integrating CTCs and ctDNA in metastatic breast cancer management
Blog
Apr 6, 2025, 12:48
Join the AUA-IBCG Bladder Cancer Forum on April 28, 2–5 PM
Blog
Apr 6, 2025, 12:45
Supporting the development of NCCPs leads to better outcomes for everyone - UICC
Blog
Apr 6, 2025, 12:43
Yüksel Ürün: Dr. Kumar Prabhash Presents ALPHA-LUNG Study at POLES25
Blog
Apr 6, 2025, 11:59
Ivy Riano: Tips for Finding a HemeOnc Job in the U.S. on a J1 Visa
Science
Apr 6, 2025, 11:58
Sahar Mansour: First prospective study in Egypt to evaluate AI in double reading for breast cancer screening
Blog
Apr 6, 2025, 11:52
Jeff Yang: Preventive Health Care Use Among Adults Eligible for Lung Cancer Screening in the US
Blog
Apr 6, 2025, 11:47
Rahul Banerjee: Hiring Myeloma Specialist at Fred Hutchinson Cancer Center
Blog
Apr 6, 2025, 11:34
Glad to attend the 3rd Chris Wood GU Onc meeting - Kidney Cancer